Xencor is trading at $28.00, up 8.36%, ahead of scheduled XmAb819 Phase 1 updates, though available coverage does not directly link the pre-market move to them. - The results are scheduled for an oral presentation at the ESMO Congress, running October 23–27 in Madrid. - Xencor has scheduled an October 26 webcast to discuss the study results. - Broad-market futures were lower, offering no clear same-direction market explanation.